IL4-induced gene 1 promotes tumor growth by shaping the immune microenvironment in melanoma

References

• Murray PJ. Amino acid auxotrophy as a system of immunological control nodes. Nature immunology 2016; 17:132-9; PMID:26784254; http://dx.doi.org/10.1038/ni.3323
   PubMed Web of Science ®Google Scholar
• Carbonnelle-Puscian A, Copie-Bergman C, Baia M, Martin-Garcia N, Allory Y, Haioun C, Crémades A, Abd-Alsamad I, Farcet JP, Gaulard P et al. The novel immunosuppressive enzyme IL4I1 is expressed by neoplastic cells of several B-cell lymphomas and by tumor-associated macrophages. Leukemia 2009; 23:952-60; PMID: 19436310; http://dx.doi.org/10.1038/leu.2008.380
   PubMed Web of Science ®Google Scholar
• Copie-Bergman C, Boulland ML, Dehoulle C, Moller P, Farcet JP, Dyer MJ, Haioun C, Roméo PH, Gaulard P, Leroy K. Interleukin 4-induced gene 1 is activated in primary mediastinal large B-cell lymphoma. Blood 2003; 101:2756-61; PMID: 12446450; http://dx.doi.org/10.1182/blood-2002-07-2215
   PubMed Web of Science ®Google Scholar
• Finak G, Bertos N, Pepin F, Sadekova S, Souleimanova M, Zhao H, Chen H, Omeroglu G, Meterissian S, Omeroglu A et al. Stromal gene expression predicts clinical outcome in breast cancer. Nature medicine 2008; 14:518-27; PMID: 18438415; http://dx.doi.org/10.1038/nm1764
   PubMed Web of Science ®Google Scholar
• Romagnani S. IL4I1: Key immunoregulator at a crossroads of divergent T-cell functions. European journal of immunology 2016; 46:2302-5; PMID: 27726138; http://dx.doi.org/10.1002/eji.201646617
   PubMed Web of Science ®Google Scholar
• Boulland ML, Marquet J, Molinier-Frenkel V, Moller P, Guiter C, Lasoudris F, Copie-Bergman C, Baia M, Gaulard P, Leroy K et al. Human IL4I1 is a secreted L-phenylalanine oxidase expressed by mature dendritic cells that inhibits T-lymphocyte proliferation. Blood 2007; 110:220-7; PMID: 17356132; http://dx.doi.org/10.1182/blood-2006-07-036210
   PubMed Web of Science ®Google Scholar
• Marquet J, Lasoudris F, Cousin C, Puiffe M, Martin-Garcia N, Baud V, Chereau F, Farcet JP, Molinier-Frenkel V, Castellano F. Dichotomy between factors inducing the immunosuppressive enzyme IL4I1 in B lymphocytes and mononuclear phagocytes. European Journal of Immunology 2010; 40:2557-68; PMID: 20683900; http://dx.doi.org/10.1002/eji.201040428
   PubMed Web of Science ®Google Scholar
• Cousin C, Aubatin A, Le Gouvello S, Apetoh L, Castellano F, Molinier-Frenkel V. The immunosuppressive enzyme IL4I1 promotes FoxP3(+) regulatory T lymphocyte differentiation. European journal of immunology 2015; 45:1772-82; PMID: 25778793; http://dx.doi.org/10.1002/eji.201445000
   PubMed Web of Science ®Google Scholar
• Yue Y, Huang W, Liang J, Guo J, Ji J, Yao Y, Zheng M, Cai Z, Lu L, Wang J. IL4I1 Is a Novel Regulator of M2 Macrophage Polarization That Can Inhibit T Cell Activation via L-Tryptophan and Arginine Depletion and IL-10 Production. PloS one 2015; 10:e0142979; PMID: 26599209; http://dx.doi.org/10.1371/journal.pone.0142979
   PubMed Web of Science ®Google Scholar
• Santarlasci V, Maggi L, Mazzoni A, Capone M, Querci V, Rossi MC, Beltrame L, Cavalieri D, De Palma R, Liotta F et al. IL-4-induced gene 1 maintains high Tob1 expression that contributes to TCR unresponsiveness in human T helper 17 cells. European journal of immunology 2014; 44:654-61; PMID: 24307243; http://dx.doi.org/10.1002/eji.201344047
   PubMed Web of Science ®Google Scholar
• Lasoudris F, Cousin C, Prevost-Blondel A, Martin-Garcia N, Abd-Alsamad I, Ortonne N, Farcet JP, Castellano F, Molinier-Frenkel V. IL4I1: an inhibitor of the CD8(+) antitumor T-cell response in vivo. European journal of immunology 2011; 41:1629-38; PMID: 21469114; http://dx.doi.org/10.1002/eji.201041119
   PubMed Web of Science ®Google Scholar
• Kato M, Takahashi M, Akhand AA, Liu W, Dai Y, Shimizu S, Iwamoto T, Suzuki H, Nakashima I. Transgenic mouse model for skin malignant melanoma. Oncogene 1998; 17:1885-8; PMID: 9778055; http://dx.doi.org/10.1038/sj.onc.1202077
   PubMed Web of Science ®Google Scholar
• Eyles J, Puaux AL, Wang X, Toh B, Prakash C, Hong M, Tan TG, Zheng L, Ong LC, Jin Y et al. Tumor cells disseminate early, but immunosurveillance limits metastatic outgrowth, in a mouse model of melanoma. The Journal of clinical investigation 2010; 120:2030-9; PMID: 20501944; http://dx.doi.org/10.1172/JCI42002
   PubMed Web of Science ®Google Scholar
• Lengagne R, Graff-Dubois S, Garcette M, Renia L, Kato M, Guillet JG, Engelhard VH, Avril MF, Abastado JP, Prévost-Blondel A. Distinct role for CD8 T cells toward cutaneous tumors and visceral metastases. Journal of immunology 2008; 180:130-7; PMID:18097012; http://dx.doi.org/10.4049/jimmunol.180.1.130
   PubMed Web of Science ®Google Scholar
• Lengagne R, Le Gal FA, Garcette M, Fiette L, Ave P, Kato M, Briand JP, Massot C, Nakashima I, Rénia L et al. Spontaneous vitiligo in an animal model for human melanoma: role of tumor-specific CD8+ T cells. Cancer research 2004; 64:1496-501; PMID: 14973052; http://dx.doi.org/10.1158/0008-5472.CAN-03-2828
   PubMed Web of Science ®Google Scholar
• Ananieva E. Targeting amino acid metabolism in cancer growth and anti-tumor immune response. World journal of biological chemistry 2015; 6:281-9; PMID: 26629311; http://dx.doi.org/10.4331/wjbc.v6.i4.281
   PubMedGoogle Scholar
• Bronte V, Brandau S, Chen SH, Colombo MP, Frey AB, Greten TF, Mandruzzato S, Murray PJ, Ochoa A, Ostrand-Rosenberg S et al. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nature communications 2016; 7:12150; PMID: 27381735; http://dx.doi.org/10.1038/ncomms12150
   PubMed Web of Science ®Google Scholar
• Lengagne R, Pommier A, Caron J, Douguet L, Garcette M, Kato M, Avril MF, Abastado JP, Bercovici N, Lucas B et al. T cells contribute to tumor progression by favoring pro-tumoral properties of intra-tumoral myeloid cells in a mouse model for spontaneous melanoma. PloS one 2011; 6:e20235; PMID: 21633700; http://dx.doi.org/10.1371/journal.pone.0020235
   PubMed Web of Science ®Google Scholar
• Toh B, Wang X, Keeble J, Sim WJ, Khoo K, Wong WC, Kato M, Prevost-Blondel A, Thiery JP, Abastado JP. Mesenchymal transition and dissemination of cancer cells is driven by myeloid-derived suppressor cells infiltrating the primary tumor. PLoS biology 2011; 9:e1001162; PMID: 21980263; http://dx.doi.org/10.1371/journal.pbio.1001162
   PubMed Web of Science ®Google Scholar
• Rei M, Pennington DJ, Silva-Santos B. The emerging Protumor role of gammadelta T lymphocytes: implications for cancer immunotherapy. Cancer research 2015; 75:798-802; PMID: 25660949; http://dx.doi.org/10.1158/0008-5472.CAN-14-3228
   PubMed Web of Science ®Google Scholar
• Douguet L, Bod L, Lengagne R, Labarthe L, Kato M, Avril M-F, Prévost-Blondel A. Nitric oxide synthase 2 is involved in the pro-tumorigenic potential of γδ17 T cells in melanoma. Oncoimmunology 2016; 5:e1208878; PMID: 27622078; http://dx.doi.org/10.1080/2162402X.2016.1208878
   PubMed Web of Science ®Google Scholar
• Koh CH, Bhoo-Pathy N, Ng KL, Jabir RS, Tan GH, See MH, Jamaris S, Taib NA. Utility of pre-treatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio as prognostic factors in breast cancer. British journal of cancer 2015; 113:150-8; PMID: 26022929; http://dx.doi.org/10.1038/bjc.2015.183
   PubMed Web of Science ®Google Scholar
• Ferrucci PF, Gandini S, Battaglia A, Alfieri S, Di Giacomo AM, Giannarelli D, Cappellini GC, De Galitiis F, Marchetti P, Amato G et al. Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients. British journal of cancer 2015; 112:1904-10; PMID: 26010413; http://dx.doi.org/10.1038/bjc.2015.180
   PubMed Web of Science ®Google Scholar
• Garg K, Maurer M, Griss J, Bruggen MC, Wolf IH, Wagner C, Willi N, Mertz KD, Wagner SN. Tumor-associated B cells in cutaneous primary melanoma and improved clinical outcome. Human pathology 2016; 54:157-64; PMID: 27107457; http://dx.doi.org/10.1016/j.humpath.2016.03.022
   PubMed Web of Science ®Google Scholar
• Ladanyi A, Kiss J, Mohos A, Somlai B, Liszkay G, Gilde K, Fejös Z, Gaudi I, Dobos J, Tímár J. Prognostic impact of B-cell density in cutaneous melanoma. Cancer immunology, immunotherapy : CII 2011; 60:1729-38; PMID: 21779876; http://dx.doi.org/10.1007/s00262-011-1071-x
   PubMed Web of Science ®Google Scholar
• Pommier A, Audemard A, Durand A, Lengagne R, Delpoux A, Martin B, Douguet L, Le Campion A, Kato M, Avril MF et al. Inflammatory monocytes are potent antitumor effectors controlled by regulatory CD4+ T cells. Proceedings of the National Academy of Sciences of the United States of America 2013; 110:13085-90; PMID: 23878221; http://dx.doi.org/10.1073/pnas.1300314110
   PubMed Web of Science ®Google Scholar
• Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nature reviews Immunology 2012; 12:253-68.
   Google Scholar
• Umansky V, Sevko A, Gebhardt C, Utikal J. Myeloid-derived suppressor cells in malignant melanoma. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology: JDDG 2014; 12:1021-7.
   Google Scholar
• Ostrand-Rosenberg S. Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity. Cancer immunology, immunotherapy: CII 2010; 59:1593-600.
   Google Scholar
• Dong C, Slattery MJ, Liang S, Peng HH. Melanoma cell extravasation under flow conditions is modulated by leukocytes and endogenously produced interleukin 8. Molecular & cellular biomechanics: MCB 2005; 2:145-59.
   Google Scholar
• Slattery MJ, Dong C. Neutrophils influence melanoma adhesion and migration under flow conditions. International journal of cancer Journal international du cancer 2003; 106:713-22.
   Google Scholar
• Hoskins MH, Dong C. Kinetics analysis of binding between melanoma cells and neutrophils. Molecular & cellular biomechanics: MCB 2006; 3:79-87.
   Google Scholar